Shots:

• The P-III withdrawal study evaluate Xywav vs PBO in 154 adults aged 19 to 75yrs. with idiopathic hypersomnia at 50 centers in seven countries
• The results showed a significant differences with Xywav compared to PBO in the 1EPs of change in ESS score and 2EPs showed an improvement in idiopathic hypersomnia symptoms including excessive daytime sleepiness, sleep inertia, prolonged sleep duration, and improved daytime performance. The safety profile was consistent with other oxybate studies
• Xywav is a lower-sodium oxybate & the FDA-approved therapy for the treatment of cataplexy or excessive daytime sleepiness in patients aged ≥7yrs. with narcolepsy & for idiopathic hypersomnia in adults

Ref: PR Newswire | Image: PR Newswire